Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis

Oslejsková, L.; Grigorian, Mariam; Hulejová, Hana; Vencovský, Jiří; Pavelka, Karel; Klingelhöfer, Jörg; Gay, Steffen; Neidhart, Michel; Brabcova, H.; Suchý, David; Šenolt, Ladislav

doi:10.1093/rheumatology/kep316

Cited by 41 publications

(46 citation statements)

References 30 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression of S100A4 is enhanced in several chronic inflammatory conditions, and concentrations are correlated with disease activity (20). S100A4 induces the production of pro-inflammatory proteins such as TNF-a, IL1b and IL6 in mononuclear cells (38).…”

Section: Discussionmentioning

confidence: 99%

“…Of note, circulating levels of these proteins have been correlated to inflammation and increased risk of CVD (19,20,21,22). Due to the close connection between the S100 proteins and the receptor for advanced glycation endoproducts (RAGE), we also analysed RAGE in order to have more information on the inflammatory process in patients with PHPT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel inflammatory biomarkers in primary hyperparathyroidism

Christensen

Fenne

Nordbø

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Primary hyperparathyroidism (PHPT) has been associated with low-grade inflammation and increased risk of cardiovascular disease (CVD). The aim of the study was to investigate systemic levels of pro-inflammatory proteins that previously have not been examined in patients with PHPT. The selection of the pro-inflammatory biomarkers included in this study, MMP9, S100A4, S100A8/A9 and the receptors sCD14 and RAGE, was based on a previous microarray screen of mRNAs in adipose tissue from PHPT patients. Design: A prospective study was conducted on a total of 57 patients with PHPT and a control group of 20 healthy blood donors. Methods: PHPT patients with normalisation of serum calcium levels after parathyroidectomy were followed for 6 months. Forty-two patients participated in the longitudinal study, in which blood samples were taken at inclusion, and 1, 3 and 6 months after surgery. Results: We observed increased serum levels of MMP9 (PZ0.029), S100A4 (P!0.001) and sCD14 (PZ0.002) in the 57 patients with PHPT compared to the control-group. During 6 months of follow up, S100A4 (PZ0.022) and sCD14 (0.002) decreased significantly, while serum levels of MMP9 increased (PZ0.025). Conclusions:The results demonstrate an increased inflammatory response in PHPT patients shown by elevated MMP9, S100A4 and sCD14 at inclusion. During the 6 months of follow-up, MMP9 increased further, possibly due to the tissue repair process after parathyroidectomy. S100A4 and sCD14 decreased after surgery demonstrating a partial reversal of the systemic inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Novel inflammatory biomarkers in primary hyperparathyroidism

Christensen

Fenne

Nordbø

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…18 This finding is consistent with the increased level of MMP-9 reported in tears of subjects with CCH. 7 In addition, Oslejsková et al 19 speculated that the S100A4 protein that is located at sites of inflammation, particularly at sites of joint destruction, might be implicated in the pathogenesis of chronic autoinflammatory diseases. It thus seems that the presence of conjunctival folds while occupying the lower tear meniscus leads to a delay in tear clearance, which in turn leads to an alteration in tear composition because delayed tear clearance increases the residency time of the contents of the tear film and may activate or potentiate ocular surface inflammation.…”

Section: Discussionmentioning

confidence: 99%

Changes in Tear Protein Profile in Patients With Conjunctivochalasis

Acera

Suárez

Rodríguez-Agirretxe

et al. 2011

Cornea

View full text Add to dashboard Cite

show abstract

“…Our results showed, that in inflamed muscle, the S100A4 protein is produced mainly by mononuclear cells present in the inflammatory infiltrates, by endothelial cells and by regenerating muscle fibres [22]. Moreover, we have previously found increased circulating levels of S100A4 in patients with rheumatoid arthritis (RA) in comparison with control individuals and demonstrated a positive correlation between S100A4 and disease activity in RA [23]. …”

Section: Introductionmentioning

confidence: 89%

“…Serum S100A4 concentrations were measured by an ELISA kit according to the manufacturer’s protocol (CycLex Co, Ltd, Ina, Nagano, Japan) as demonstrated elsewhere [23]. The analysis was performed using the ELISA reader SUNRISE (Tecan, Salzburg, Austria) at a wavelength of 450 nm.…”

Section: Methodsmentioning

confidence: 99%

The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies

et al. 2014

View full text Add to dashboard Cite

IntroductionThe aim was to evaluate S100A4 protein as a biomarker of disease activity and potential cancer development in patients with myositis.MethodsSerum levels of S100A4 were determined in 43 dermatomyositis (DM), 39 polymyositis (PM) and 22 cancer associated myositis (CAM) patients as well as in 77 healthy controls. The associations between S100A4 levels, inflammation, disease activity, muscle strength and cancer development were evaluated.ResultsAll myositis patients had significantly higher serum levels of S100A4 protein compared to healthy controls (median (IQR): 31.5 (17.4 to 59.5) versus 23.8 (14.5 to 33.7) ng/ml, P <0.05). In patients with PM, serum levels of S100A4 protein were significantly higher than in healthy controls (41.6 (24.2 to 123.1) versus 23.8 (14.5 to 33.7) ng/ml; P <0.001) as well as in patients with DM (26.7 (11.3 to 47.5) ng/ml; P <0.05). The levels of S100A4 were comparable between myositis with and without cancer. In all myositis patients, serum S100A4 levels correlated with MYOsitis disease ACTivity assessment (MYOACT) score (r = 0.34; P = 0.001), constitutional (r = 0.30; P = 0.003), pulmonary (r = 0.43; P = 0.0001) and extramuscular disease activity (r = 0.36; P = 0.0001), as well as with creatine phosphokinase (r = 0.27; P = 0.015) and lactate dehydrogenase (r = 0.37; P = 0.002) or c-reactive protein (CRP) levels (r = 0.24; P = 0.038). Multiple regression analysis showed significant association between S100A4 serum levels and extramuscular disease activity (β = 0.552; P = 0.002) in PM patients and with MYOACT (β = 0.557; P = 0.003) and CRP levels (β = 0.391; P = 0.029) in DM patients.ConclusionsCirculating levels of S100A4 are elevated in patients with myositis and associate with several disease activity parameters, particularly with extramuscular components. No relation between S100A4 levels and presence of cancer associated myositis was found.Electronic supplementary materialThe online version of this article (doi:10.1186/s13075-014-0468-2) contains supplementary material, which is available to authorized users.

show abstract

Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis

Cited by 41 publications

References 30 publications

Novel inflammatory biomarkers in primary hyperparathyroidism

Novel inflammatory biomarkers in primary hyperparathyroidism

Changes in Tear Protein Profile in Patients With Conjunctivochalasis

The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies

Contact Info

Product

Resources

About